

GLAXOSMITHKLINE PLC

Form 6-K

December 16, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 16 December 2016

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

GlaxoSmithKline plc

(the 'Company')

Notification of Transfer of Shares out of Treasury

Pursuant to the Financial Conduct Authority's Listing Rule 12.6.4, the Company hereby notifies the market of the following:

On 15 December 2016, the Company transferred 33,300,000 ordinary shares of 25 pence each ('Ordinary Shares') that were held by the Company in treasury ('Treasury Shares') to the GlaxoSmithKline Employee Benefit Trust to be used specifically to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received was £15.07 pence per Ordinary Share.

Following the transfer, the Company's issued share capital consisted of 5,368,238,025 Ordinary Shares, of which 458,205,950 were held as Treasury Shares.

Therefore, the total number of voting rights in the Company is 4,910,032,075. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

V A Whyte
Company Secretary

16 December 2016
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: December 16, 2016

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc

